Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Chewy

Moderna

Moderna aims to launch 15 new products over the next few years. Vertex Pharmaceuticals is waiting for a regulatory decision an exciting new product.

Looking for Growth? These Companies' Revenue May Skyrocket

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor, for the treatment of children with cystic fibrosis (CF) ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance.

Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that three of its researchers have been awarded the 2024 Breakthrough Prize in Life Sciences “for developing life-transforming drug combinations that repair the defective chloride channel protein in patients with cystic fibrosis.” Specifically, the award celebrates the work of Paul Negulescu, Ph.D., Fredrick Van Goor, Ph.D., and Sabine Hadida, Ph.D., who have worked together to lead cystic fibrosis (CF).

Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 13, 2023 11:30 AM ET Company Participants Charlie Wagner - EVP and CFO Reshma Kewalramani - President and CEO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Well, thanks, everybody, for joining us. I'm Terence Flynn from the U.S. biopharma analyst here at Morgan Stanley and we're very pleased to be hosting Vertex for this session.

Vertex Pharmaceuticals Incorporated (VRTX) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired an undisclosed discovery-stage GPCR program. Under the terms of the agreement, Vertex will be responsible for continuing the research and development.

Septerna Announces Novel GPCR-targeted Program Acquired by Vertex

Amazon

Mastercard

Amazon should deliver strong growth over the short term and long term. Mastercard's moat and growth opportunities make it an attractive pick.

A Bull Market Is (Still) Coming: Here Are 3 Spectacular Stocks to Buy Sooner Rather Than Later

Eli Lilly

Regeneron Pharmaceuticals

Eli Lilly is a healthcare giant poised to get even bigger. Regeneron Pharmaceuticals has nowhere to go but up.

3 Unstoppable Growth Stocks to Buy Right Now

Vertex Pharmaceuticals has many avenues for chasing growth both big and small. Its cystic fibrosis medicines continue to remain a rock-solid base of revenue.

1 Top Pharma Growth Stock to Buy Today and Hold Forever

Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.

2 Top Biotech Stocks to Buy in September

Vertex Pharmaceuticals is trying to replicate its winning cystic fibrosis formula in other areas. These efforts could yield even better financial results than its potential gene-editing therapy.

Could These Be Vertex Pharmaceuticals' Most Promising Candidates?

AT&T

U.S. Bancorp

September is not known as a good month to buy stocks. In fact, historically it's the worst month.

September Rally? 3 Stocks to Buy Before Liftoff

Pfizer

Pharma companies often have detailed plans for when new revenue will occur. They also sometimes describe periods when sales will be shrinking.

3 Must-Know Tricks for Investing in Big Pharma Stocks

AbbVie

Recursion Pharmaceuticals

In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging, even when zeroing in on established firms with market-ready drugs and expansive research and development pipelines.

3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains

Madrigal Pharmaceuticals

Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF (NASDAQ: IBB ), is down 5% since Jan. 27.

The 3 Best Biotech Stocks to Buy Now: September 2023

Fiverr

PayPal

Visa

Wall Street volatility is a blessing in disguise for opportunistic long-term investors looking to pounce. Five game-changing businesses have the macro and company-specific catalysts needed to make their patient shareholders meaningfully richer over time.

5 Surefire Stocks That Can Build Generational Wealth in 20 Years

D.R. Horton

D.R. Horton is a Warren Buffett stock that's a bargain and has great growth potential. Vertex Pharmaceuticals has multiple growth drivers that could make it an even bigger winner than it already is.

2 Spectacular Growth Stocks You Can Buy in September With No Hesitation

Intellia Therapeutics

Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority voters. This commitment to economic inclusivity bodes well for overall economic health and long-term growth.

The 3 Most Promising Biotech Stocks to Own Now

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Morgan Stanley 21st Annual Global Healthcare Conference. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.

Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13

Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio.

Vertex (VRTX) Outperforms Industry Year to Date: Here's Why

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene ther.

Vertex Appoints E. Morrey Atkinson, Ph.D.

Novo Nordisk

Vertex, Eli Lilly, and Novo Nordisk are growing their sales rapidly. All three biotechs have solid portfolios and highly promising pipelines.

3 Top Growth Stocks I'd Buy Right Now Without Hesitation

Altria

Walmart

The stock market recovered nicely from last year's debacle. The Nasdaq Composite Index in particular went from a 34% loss in 2022 to a 29% gain so far this year.

Got $600? Here are 3 No-Brainer Stocks You Absolutely Must Buy

Novartis

Vertex Pharmaceuticals' innovative potential in areas with unmet needs is proving to be a major strength. Novartis is shaking up its business in ways that should help it deliver much stronger returns in the future.

2 Excellent Stocks to Buy and Hold Forever

Exelixis

iShares Nasdaq Biotechnology ETF

The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.

3 Strong Biotech Performers To Watch As Sector Nears Breakout

IQVIA Hlds

West Pharmaceutical Services

Zoetis

For investors, tracking the stocks that are up in what has otherwise been a grim year for drugmakers can help identify trends in the market.

News for Vertex Pharmaceuticals Stock (VRTX)